Novavax, Inc.’s vaccine against SARS-CoV-2 is effective at preventing infection with the UK and South African variant strains of the virus, according to new study results, but consistent with other vaccine results, the protection is lower than against the original strain.
The Gaithersburg, MD-based company released data from two studies, a Phase III study in the UK and a Phase IIb study looking at the South African variant, on 28 January, the same day that the South African variant was first reported in the US, in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
